Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFOI3T)

Drug Name

ENV-101 Drug Info

Synonyms

Taladegib

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hedgehog signaling pathway (HS pathway)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-04449913	DMSB068	Chronic myelomonocytic leukaemia	2A40	Approved	[3]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[4]
Patidegib	DM2NJYC	Basal cell carcinoma	2C32	Phase 2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hedgehog signaling pathway (HS pathway)	TT4LXBC	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04968574) A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF). U.S.National Institutes of Health.
2	Development of taladegib as a sonic hedgehog signaling pathway inhibitor. Arch Pharm Res. 2017 Dec;40(12):1390-1393.
3	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)